Split doses of Methotrexate in patients with moderate to severe Psoriasis M.J.M. Rodríguez-Zúñiga, F. Cortez-Franco, E. Qujiano-Gomero

52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience F.J. Melgosa Ramos, A. Mateu Puchades, J. Matáix-Díaz, L. Schneller-Pavelescu, I. Belinchón-Romero, S. Santos Alarcón

Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time J.M. Carrascosa, N. Rivera, I. Garcia-Doval, G. Carretero, F. Vanaclocha, E. Daudén, F.J. Gómez-García, P. De-la-Cueva-Dobao, E. Herrera-Ceballos, I. Belinchón, M. Alsina, J.L. Sánchez-Carazo, M. Ferrán, J.L. Lopez-Estebaranz, B. Pérez-Zafrilla, M. Llamas, R. Rivera, C. Ferrándiz